An idea is born, Simon and Michal lay the foundation in Basel, Switzerland.
In collaboration with FHNW (University of Applied Sciences Northwestern Switzerland) , RXcel has successfully conducted a proof-of-concept experiment, funded by Innosuisse. This study demonstrated a statistically significant difference of effector protein production in specific cell lines with and without CDKN2A, using fluorescent reporter constructs (eGFP). The underlying concept has been discussed with scientists in the relevant fields, who have expressed confidence in its potential.
Dr. Marion Salvador joins as a Scientific Consultant. Private funding has enabled us to revalidate and optimize in vitro results in close collaboration with FHNW.
RXcel signs a Memorandum of Understanding with the Czech Academy of Sciences. This also marks the beginning of our collaboration with Prof. Petr Svoboda and his group.
Prof. Ghazaleh Tabatabai joins as another Strategic Consultant and brings long-standing experience from clinical practice and research in the field of neuro-oncology.
In close collaboration with our academic partners, we are currently optimizing our target RNA, aiming to reach in vivo readiness by Q1 2027. This includes the integration of new RNA designs to build a versatile therapeutic platform, along with ongoing validation of the molecular mechanism and assessment of potential off-target effects. To advance into in vivo studies, additional funding will be required, and RXcel has initiated early-stage discussions to secure the necessary resources.